secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2026-07-17T20:05:26+00:00
Accession:  0001104659-26-084617
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics amends Series C Preferred beneficial ownership limit from 4.99% to 9.99%
--------------------------------------------------------------------------------

- Filed Amended and Restated Certificate of Designation for Series C Non-Voting Convertible Preferred Stock.
- Beneficial ownership limitation increased to 9.99% from 4.99%.
- Amendment approved by majority of Series C holders and Board of Directors.
- No new securities issued; only scrivener's errors corrected.
- Effective July 16, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926084617/0001104659-26-084617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926084617/tm2620727d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-084617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer